Literature DB >> 16234443

The pharmacokinetics of linezolid in the non-inflamed human eye.

J I Prydal1, D R Jenkins, A Lovering, A Watts.   

Abstract

AIM: This study describes the ocular pharmacokinetics of linezolid, an antibiotic with broad spectrum activity against those Gram positive bacteria that are the most frequent cause of postoperative endophthalmitis.
METHOD: Patients undergoing routine cataract surgery were given a single oral 600 mg dose of linezolid at a variable time before surgery. Aqueous and serum levels of linezolid were assayed by high performance liquid chromatography, and a pharmacokinetic curve constructed from the pooled results.
RESULTS: Orally administered linezolid rapidly achieves levels in the aqueous of non-inflamed eyes that exceed the concentration required to kill Gram positive bacteria (maximum mean concentration 6.8 (SD 1.2) microg/ml at 2-4 hours post-dose). An effective concentration is maintained for at least 12 hours, the standard interdose interval for this antimicrobial.
CONCLUSION: Linezolid offers the possibility of a rapid, oral approach to effective treatment of most cases of postoperative endophthalmitis, with the potential of improving visual outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234443      PMCID: PMC1772914          DOI: 10.1136/bjo.2005.073700

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.

Authors:  A M Lovering; J Zhang; G C Bannister; B J A Lankester; J H M Brown; G Narendra; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

2.  Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study.

Authors:  D P Han; S R Wisniewski; L A Wilson; M Barza; A K Vine; B H Doft; S F Kelsey
Journal:  Am J Ophthalmol       Date:  1996-07       Impact factor: 5.258

Review 3.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Epidemiology of infective endophthalmitis in France. The French Collaborative Study Group on Endophthalmitis.

Authors:  A Fisch; A Salvanet; T Prazuck; F Forestier; L Gerbaud; G Coscas; C Lafaix
Journal:  Lancet       Date:  1991-11-30       Impact factor: 79.321

5.  Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

Authors:  A P Johnson; M Warner; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

6.  Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis.

Authors:  N Okhravi; H M Towler; P Hykin; M Matheson; S Lightman
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

Review 7.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

8.  National outcomes of cataract extraction. Endophthalmitis following inpatient surgery.

Authors:  J C Javitt; S Vitale; J K Canner; D A Street; H Krakauer; A M McBean; A Sommer
Journal:  Arch Ophthalmol       Date:  1991-08

9.  Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration.

Authors:  E García Vázquez; J Mensa; Y López; P Díaz Couchard; D Soy; J R Fontenla; M Sarasa; X Carné; E Montull
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1995-12
View more
  2 in total

1.  In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms.

Authors:  Bruna Leite; Fernanda Gomes; Pilar Teixeira; Clovis Souza; Elisabeth Pizzolitto; Rosário Oliveira
Journal:  Curr Microbiol       Date:  2011-07-15       Impact factor: 2.188

2.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.